Canadian innovators oppose new bill to reform medicines access scheme
This article was originally published in SRA
Executive Summary
The introduction of a new bill designed to reform Canada’s Access to Medicines Regime would remove “almost all relevant protections on intellectual property”, the president of Canada’s Research-Based Pharmaceutical Companies (Rx&D) has warned.